NCT05227742View on ClinicalTrials.gov

Exploratory Study of Low Dose Psilocybin

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Demoralization
Interventions
DRUG

Psilocybin

Participants will receive oral psilocybin once per week for 5 weeks.

DRUG

Placebo

Participants will receive inert placebo once per week for 5 weeks.

Trial Locations (1)

35209

RECRUITING

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

Diamond Therapeutics Inc.
All Listed Sponsors
collaborator

Diamond Therapeutics Inc.

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT05227742 - Exploratory Study of Low Dose Psilocybin | Biotech Hunter | Biotech Hunter